SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " drug " 1,588 found 🔀 AI-powered Shuffle
Health Brief: Exclusive | States line up for Medicaid drug pilot
At least 19 have applied to the Trump administration’s drug-pricing experiment offering internationally benchmarked prices under Medicaid
Bill Directing Federal Health Officials To Track Testing For Marijuana And Other Drugs In Hospital ERs Set For House Vote This Week
The U.S. House of Representatives is expected to vote on a bill this week to require the Department of Health and Human Services (HHS) to study how prevalent drug testing for marijuana, fentanyl and other drugs is in hospital emergency departments. The legislation, which cleared the House Energy and Commerce Committee in a unanimous 46-0 […]
Drugs for autoimmune diseases are pricey. This bill could switch patients to a cheaper one
Nearly 25,000 Californians could get switched to a cheaper drug next year — unless their doctor objects.
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Deliver Oral Comments at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
Sarit Hashkes, President of Filament Health Corp., will provide oral remarks at the United States Food and Drug Administration public hearing "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs", being held later today, September 14, 2026Toronto, Ontario--(Newsfile Corp. - September 14, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal...
Kentucky looks to expand GLP-1 drug access for Medicaid patients
A federal program could help Kentuckians on Medicaid get GLP-1 drugs, but outdated state rules block the path.
Seattle-area business leaders call on city to halt open-air drug markets, add services
In a letter addressed to the Mayor of Seattle, and the city council, dozens of business minds requested that the city take a hard look at public safety and drug
Political debate over AI intensifies amid warnings about ‘catastrophic risk’
(CNN) — The debate around artificial intelligence is ramping up in Washington, with Democratic lawmakers sounding alarms on the dangers they say the technology poses and Republican leaders suggesting those concerns are inflated and secondary to winning the AI race with China.Some Democratic lawmakers last week pressured House Speaker Mike Johnson to reconvene the chamber immediately to work on AI regulation, citing what they describe as the “catastrophic risk posed by advanced artificial intelligence.” But the Louisiana Republican on Sunday resisted those calls, instead saying industry leaders should meet with lawmakers to find “balance” in any potential guardrails.“If Congress just races in and does some sort of emergency session to try to regulate AI, we will lose the race to China, and that is a threat to every single American,” Johnson said on CNN’s “State of the Union.”Meanwhile, former President Barack Obama told Democrats to make artificial intelligence regulation a central part of their agenda during a private fundraiser Thursday, warning that the technology could be dangerous “if we don’t get on top of it.”In a fireside chat with House Democratic Leader Hakeem Jeffries, Obama said whoever runs in the 2028 presidential election should have a “very clear plan” on AI, adding that he saw the need for a “blueprint” on AI guardrails even at the end of his presidency a decade ago.“Certainly, if I were running for president next year, this would be one of my central agendas, and I would have a very clear plan, and I would talk about this, and I would say, ‘Here’s our plan for safety, here’s our plan for making sure our kids are not corrupted by this,’” he said, per excerpts of the remarks provided to CNN by his office. Obama’s remarks were first reported by the New York Times.Concerns over the rapid acceleration of AI reached a fever pitch after Anthropic CEO Dario Amodei wrote in a 3,800-word essay Saturday that the race to develop artificial intelligence is in dire need of a slowdown. The call to action came after an OpenAI test model breached the Hugging Face online platform, deepening concerns about cybersecurity.In an exclusive interview with CNN’s Anderson Cooper on Saturday, Amodei called on industry leaders to work together to avoid “the wrong paths” and the possibility of AI harming humanity.One Anthropic researcher, Jacob Coxon, resigned from the firm over worries that the industry wasn’t doing enough to prevent AI from destroying humanity by the end of the decade.Obama said Democrats need a plan to get their agenda on AI underway should they win the House majority in this year’s midterms.Speaking to Jeffries, who is presumed to be speaker of the House should Democrats prevail in November, Obama said, “Once you are speaker, I would strongly urge that the Democrats put together a framework for a very public conversation, and you can break it out into three or four or five issues.”Obama stressed that the framework should be centered on the reality that the technology can’t be stuffed “back into a box.”“This is something that is moving very fast in private hands, and if we don’t get on top of it, I think can be dangerous. If we do get on top of it, I do think it’s beneficial,” Obama said, laying out examples of AI’s potential use in drug development and finding pathways to a clean energy future.“We don’t want to shut off those opportunities, but we have to understand that this is a tool,” he said.Jeffries agreed with the former president in a statement provided to CNN on Sunday.“President Obama is correct that decisive action must be taken on Artificial Intelligence,” he said, adding, “In the majority, we will move urgently on this issue with a legislative response that recognizes the importance of American companies continuing to lead in the Artificial Intelligence area, while putting in place meaningful guardrails that protect the American people from bad actors and the very real damage that can be done to humanity.”Jeffries also accused Republicans of having “abdicated their responsibility to govern” and said Democrats “will not repeat their error.”A source familiar with Obama’s thinking said the former president sees Amodei’s letter and similar reaction from other tech moguls as an encouraging development.But President Donald Trump waved off their concerns, saying he is not worried about any existential threat posed by AI, focusing instead on the US winning in its development of the technology over China.“We’re leading China in AI. We’re the most sophisticated country in the world, and frankly, I want to keep it that way,” Trump said to reporters at the Amgen Irish Open on Sunday.About the concerns expressed by Democrats and others over the technology, the president said, “I think you have a lot of negative forces that are bringing it up that shouldn’t be bringing it up, and they’re bringing up things that won’t happen.”One of Trump’s top economic advisers, Kevin Hassett, also rejected the calls for slowing the technology down, saying on Sunday the bigger concern is a scenario in which a “malevolent actor has access to an AI that’s better than the one we have that can protect us.”Hassett, the National Economic Council director, said on “State of the Union” the White House may hold meetings this week about addressing Amodei’s concerns, but he did not specify whether Trump had floated greater safeguards.“I have concerns that if we don’t win AI, we’re going to be put in a very bad position,” Hassett said. “We are leading China right now.”CNN’s Alison Main and Molly English contributed to this report.The-CNN-Wire™ & © 2026 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved.THE-CNN-WIRE (TM) & © 2026 CABLE NEWS NETWORK, INC., A TIME WARNER COMPANY. ALL RIGHTS RESERVED.
Bone Health Without the Hype
I am at the Australasian Menopause Society meeting and we had a fantastic lecture on Bone Health on Day 2, called, “Everything you need to know about bones - except the boring bits!” Spoiler alert, there were no boring bits. The lecture was given by Dr. Amanda Beech, who is a senior staff specialist in Obstetric Medicine and Endocrinology at the Royal Hospital for Women, where she is director of the Bone Density Unit. I want to summarize my top 10 take-aways for you. Share Osteoporosis is a disease of low bone mass, disruption of bone microarchitecture, and fragility of the skeleton. It is a silent disease…until someone develops a fracture. The diagnosis of osteoporosis is based on either fragility/minimal trauma fractures or a T-score of less than -2.5 on a DXA (Dual-Energy X-ray Absorptiometry) or bone scan. It is important to recognize that about 50% of minimal trauma fractures occur when women have low bone mass (often referred to as osteopenia), but not osteoporosis. This tells us that bone strength is more complicated than a number on a DXA report. I am going to add a little here that wasn’t in the talk (one can only include so much in 25 minutes), as many women might read the above paragraph and think, “Shouldn’t we be treating everyone with low bone mass if this is when 50% of the fractures occur?” Many fractures happen for women with low bone mass because there are so many women with low bone mass –it is a statement about the population on a whole, not about the fracture risk of low bone mass. For you as an individual, bone density is only one component of fracture risk and many women with lower bone mass will not have a significantly elevated fracture risk. This is why individualized risk assessment matters. Subscribe We build bone in our teens and twenties, and by the time we are about thirty we have reached peak bone mass. This is why, when we discuss risk factors for osteoporosis, it is important to consider factors that might have affected us in our teens and twenties when we were actively building bone, such as nutritional restriction/energy imbalance. It is important to ask women about a history of eating disorders, and for those with such a history, getting a bone scan in perimenopause or at age 50 is likely warranted. (This image below isn’t from the talk, but is similar to one that was). Bone mass is relatively stable until about two years before the final menstrual period, and perimenopause marks a time of rapid bone loss for women. Using urinary markers of bone loss we know that the time of significantly accelerated bone loss starts about 1 year before the final period and ends about 2 years after the final period. The Study of Women’s Health Across the Nation (SWAN) shows that over the menopause transition women lose an average of 10.6% of the bone at their lumbar spine and 9.1% at the femoral neck While this wasn’t covered in the lecture, I want to add that the rapid bone loss during perimenopause is clearly related to more than estradiol, because during this time estradiol levels can be erratic and not uniformly low. Bone loss during perimenopause is likely a multi-hormone event. For example, rising FSH (follicle stimulating hormone) tracks with bone loss better than estradiol, and there is evidence that FSH may act directly on bone. While decreased estrogen matters, there is clearly more going on. FSH and bone is an active area of research. Subscribe Screening for osteoporosis was recommended fairly broadly before age 65, and was taken from the “Practitioner’s Toolkit for Managing Menopause,” from Monash University. Here is a screenshot from the toolkit that was used as a slide: I am going to add a little bit more about body weight here for clarification. Low body mass (typically 152.1 lb): 0 points (risk neutral) 60–69 kg (132.3–152.1 lb): 3 points (adds some risk)
Science Snapshots: September 13, 2026
Explore groundbreaking discoveries in human drug use, sleep regulation, and the surprising effects of charged water on Teflon.
Scientists find Ozempic may slow aging itself
Semaglutide helped older healthy mice live longer while improving memory, muscle function, blood sugar control, and several biological signs of aging. Its effects went beyond those seen with calorie restriction, raising the possibility that GLP-1 drugs could tap into a separate biological pathway linked to longevity.
ACA, Medicare or health insurance through work? Your health insurance bills are about to go up
The premium increases stem in part from rising healthcare costs, including higher prices for medical care and expensive prescription drugs.
Colombia to Start Aerial Spraying of Coca Crops Despite Health Worries
The plan — quickly challenged by a local court — came days after Colombia’s president and the U.S. secretary of state, Marco Rubio, discussed stronger measures against drug trafficking.
Posts touting mebendazole as cancer treatment go beyond the science
The anti-parasitic drug mebendazole has shown preclinical efficacy in targeting multiple cancers, but experts say social media posts calling it a "cure" go too far. Additional clinical trials in humans are necessary to prove when, at what dosage, and in which treatment combinations it could make an impact.
Posts touting mebendazole as cancer treatment go beyond the science
The anti-parasitic drug mebendazole has shown preclinical efficacy in targeting multiple cancers, but experts say social media posts calling it a "cure" go too far. Additional clinical trials in human...
Life Sciences Companies Present Live at the September 17 Virtual Investor Forum
Live Presentations and Q&A Across Oncology, Fibrosis, Drug Delivery, Antibiotics, Cannabinoid Therapeutics, and Respiratory Imaging A Global Lineup Presents Live Online: 30-Minute Sessions, Audience Q&A, Replays On Demand NEW YORK, NY - Sept...
The dirtiest places on an airplane; testing for a breast cancer gene mutation; the evolution of esophageal cancer; plus other stories with Vanderbilt Health sources
William Schaffner, MD, Professor of Preventive Medicine, was quoted by several news outlets about public health issues, including: WKRN News 2 (heat-related illness); NBC News (how bad will flu and COVID be this winter?); AAA’s The Extra Mile (the dirtiest places on an airplane); WKRN News 2 (again) (measles in Tennessee); and The Tennessean and Healthline (new COVID vaccines). Schaffner also spoke to the EMJ European Medical Journal for a Q&A interview. Tuya Pal, MD, Professor of Medicine, was quoted in a New York Times story about testing for a breast cancer gene mutation. Michael Gibson, MD, PhD, Professor of Medicine, was quoted in a MedPage Today story about the epidemiologic evolution of esophageal cancer. Medpage Today writer Shannon Fritz quoted Shravani Durbhakula, MD, Associate Professor of Pain Medicine, who answered questions about a street drug called cychlorphine. Becker’s Behavioral Health picked up the story. WSMV Channel 4 News reporter Diana Rocco interviewed Michael Caucci, MD, Associate Professor of Psychiatry and Obstetrics and Gynecology, for a story about postpartum psychosis and the trial of Lindsay Clancy.
How Did a Heart Drug With So Much Promise Fall So Flat?
Cardiologists are struggling to figure out why a drug that should have prevented heart attacks didn’t work at all.
Your next prescription could be treating a side effect from the last one
A major Ontario study found 24 common medication chains in which one drug’s side effects can be mistaken for a new medical problem, leading to another prescription. Researchers say closer medication reviews, pharmacist involvement, and automated alerts could help prevent these potentially harmful prescribing cascades.
Gone Too Hard? Regular Erectile Dysfunction Drug Use Raises Risk of Vision Loss, Study Finds
It doesn't just affect systems below the belt.
The science behind the 2026 Cyclospora Outbreak
This summer, a common salad ingredient became the center of a major foodborne illness outbreak across the United States. The Food and Drug Administration (FDA)…
Fact check: Trump, RFK Jr. and others make false claims on night 2 of GOP convention
(CNN) — President Donald Trump delivered another rapid-fire series of false claims on the second night of Republicans’ midterm convention on Thursday. Health Secretary Robert F. Kennedy Jr. did his own barrage of wrongness. And various other speakers uttered statements that were untrue, misleading or missing critical context.Here is a fact check of some of the assertions from the final day of the convention. This is not intended as a comprehensive list of Thursday’s falsehoods.Trump’s many false claimsTrump made numerous false claims, some of which he also made in his longer speech Wednesday.Trump claimed that there were “no empty seats” in the Dallas arena as he spoke Thursday, which was visibly untrue. CNN White House correspondent Alayna Treene, who was there, wrote in a live chat right after Trump made the claim that “I’m looking at rows of empty seats” and that “the idea that there are ‘no empty seats’ is just laughably untrue,” though she also said the room was mostly full. Trump has for years made false claims about supposedly never having had an empty seat.Trump further inflated one of his favorite fictional figures, claiming Thursday that “$22 trillion” in investment has come into the US; on Wednesday, he had put it at “over $20 trillion,” and even that lower figure has no apparent basis in reality. As of the time he spoke Thursday, the White House’s own website claimed there had been “$11.2 trillion” in “major investment announcements” this term, not “over $20 trillion,” and the White House figure was itself a major exaggeration of actual investment.Trump, talking about elections, lied that “there’s never been bigger cheaters” than Democrats; there is no basis for broadly describing Democrats as election cheaters. For the second straight night, Trump falsely claimed that the Biden administration allowed “25 million people” to pour into the country, though that number is nowhere close to correct. Trump again falsely claimed that former President Joe Biden and other Democrats “created the worst inflation in American history,” though even peak Biden-era inflation, 9.1% in June 2022, was far from the all-time record of 23.7%; it was a 40-year high, but the rate then fell sharply before Trump returned to office.Trump also baselessly claimed that Democrats would “defund the police” and give “voting rights and welfare to 25 million illegal aliens” if they won the midterms. Republicans will still control the White House in 2027 and 2028 and the president would be in position to veto any such changes if a Democratic-controlled Congress sought to make them, but there is no indication that Democrats want to do so. Also, even groups favoring strict immigration policies estimate that the total undocumented population is far less than “25 million” or even 20 million.As he did Wednesday, Trump claimed the US now has the world’s lowest prescription drug prices. The assertion is so broad that it is unclear what exactly Trump is referencing. But experts told CNN they highly doubt that the prices for brand-name drugs in the US are generally less than they are in other countries, and the Trump administration has not provided details to prove the claim.“It’s tough to claim that you’re getting the lowest prices anywhere in the world and then also not have any evidence to support that,” said Andrew Mulcahy, a senior health economist at RAND, while Diederik Stadig, senior healthcare economist at financial institution ING, said, “To say that the US now has the lowest drug prices in the world is at this moment not true.”And as he did Wednesday, Trump said “more Americans are working today than ever before” – which is true but nearly meaningless, since the number of people working in the US generally rises over time simply because the population rises over time.“There are more Americans working because there are more Americans. That’s the entire analysis,” Justin Wolfers, a University of Michigan professor of public policy and economics, wrote in his newsletter in August.RFK Jr.’s false claims on the pandemic, Trump’s record and moreFalse claim about Democrats and the 2024 electionKennedy unsuccessfully ran for the 2024 Democratic presidential nomination before withdrawing to run as an independent and then eventually endorsing Republican candidate Donald Trump. In Kennedy’s Thursday convention speech, he complained of how the Democrats handled the nomination race.At one point, he said, “For the first time in history, they cancelled their own convention. No voter ever cast a primary ballot for Kamala Harris, no elected delegate was ever consulted; the party of ‘No Kings’ simply anointed a queen.”Kennedy is entitled to express unhappiness about how quickly Democratic leaders coalesced around then-Vice President Harris after Biden unexpectedly dropped out of the race in July 2024, after the primaries were over and less than four months from Election Day. But it’s not true that the party canceled its convention or that delegates didn’t get any say.The convention was held; it was a four-day event in Chicago in August 2024. Democratic convention delegates officially nominated Harris in a virtual roll call vote in advance of the convention. It’s true that Harris was the only candidate on the roll call ballot, but that’s because she was the only candidate who gathered enough delegate signatures to appear on the ballot.It’s clear that party elites’ backing of Harris played a key role in the unusual nomination process. But Kennedy’s specific allegations that the convention was abandoned and delegates were cut out of the process are not true.False claim that Democrats closed ‘every church’ during the Covid-19 pandemicWhile attacking Democrats, Kennedy claimed that, during the Covid-19 pandemic, “They closed every church in our country for a year.”It’s not true that every church in the country was closed for a year, nor even that every church in a Democratic state was closed for a year.Every state issued some type of guidance or order about social distancing during the Covid-19 pandemic, but many states – including some led by Democrats and some led by Republicans – incorporated religious exemptions into those limitations on social interactions.According to a Pew Research Center analysis from April 2020, 15 states allowed religious gatherings to continue without a limit on their size. That set of states included Colorado, Michigan and Pennsylvania, which all had Democratic governors. And at least two states with Republican governors, Alaska and Idaho, were among the states that prohibited religious gatherings at least briefly.False claim that Trump ‘ended nine wars’Trump has repeatedly claimed that he has ended “eight wars.” Kennedy went one higher on Thursday, declaring, “President Trump has ended nine wars.”That’s false. Trump hasn’t even ended eight wars.Trump’s list of eight includes two situations that were never actually wars during his tenure: a diplomatic dispute between Egypt and Ethiopia and a mysterious supposed situation between Serbia and Kosovo. The list also includes a war, involving Rwanda and the Democratic Republic of Congo, that hasn’t actually ended despite a peace agreement brokered by the Trump administration.In addition, the list includes the war between Israel and Hamas, but Israel continues to conduct frequent attacks in Gaza despite a US-brokered ceasefire agreement. And it includes the brief 2025 conflict between Israel and Iran, though Israel proceeded to join the US in starting another war against Iran in 2026.Claim about reversing a decline in longevityKennedy speaking of the Trump administration, claimed Thursday: “We have now reversed a 30-year decline in longevity. “Kennedy referenced preliminary data that he said he had received from the US Centers for Disease Control and Prevention this week, but it’s unclear what metric of longevity he’s referring to.CDC data shows that US life expectancy had been steadily increasing for decades before a sharp drop during the Covid-19 pandemic. Life expectancy had already started to rebound in 2022, under the Biden administration, and reached a new record high in 2024 before Trump’s second term began.Preliminary data shared by the CDC in July suggests that life expectancy probably hit another record high in 2025.CNN has reached out to HHS for clarification on Kennedy’s comments.Claim that Democrats ‘lost 360,000 children’Speaking about Democrats, Kennedy said: “They somehow lost 360,000 children and they turned our federal government into the biggest child trafficking operation in world history.”Trump and other Republicans have made similar claims. But there’s no basis for the assertion that Democrats “lost” so many children or that the federal government was engaged in human trafficking.A 2024 report from the inspector general for the Department of Homeland Security said Immigration and Customs Enforcement had reported that more than 32,000 unaccompanied migrant children failed to appear as scheduled for immigration court hearings after being released or transferred out of custody between fiscal years 2019 and 2023 – a period that, notably, includes two years and four months under the first Trump administration. The report also said that 291,000 unaccompanied migrant children during this period were not given notices to appear in court.The report said that ICE had “no assurances” these children “are safe from trafficking, exploitation, or forced labor.” But it did not say all the children were actually “lost” and did not definitively assert that any of them were trafficked – let alone that the government was somehow involved in a trafficking operation. And, again, the report spanned parts of both a Republican administration and a Democratic administration.Aaron Reichlin-Melnick, senior fellow at the American Immigration Council, told CNN in 2024: “Long story short, no, there are not 320,000 kids missing. 32,000 kids missed court. That doesn’t mean they’re missing, it means they missed court (either because their sponsor didn’t bring them or they are teenagers who didn’t want to show up). The remaining 291,000 cases mentioned by the (Office of the Inspector General) are cases where ICE hasn’t filed the paperwork to start their immigration court cases.”Vance on inflation, crime and taxes on Social SecurityA false claim about the media and Biden-era inflationVice President JD Vance mocked the media during part of his speech on Thursday. But he made a false claim about Biden-era inflation while lampooning how the media supposedly challenged him over another false claim on that subject.Vance said: “The president and I would go during a campaign, we’d say, ‘You know, inflation is as high as it’s been in 100 years,’ and the fake news would say, ‘No, no, no, it’s as high as it’s been in 68 years.’ That ain’t good, ladies and gentlemen.”Mainstream journalists, at least, wouldn’t say that inflation under Biden was as high as it had been “in 68 years.” Rather, CNN and others noted that peak inflation under the Biden administration, 9.1% in June 2022, was the highest in about 40 years.Vance is entitled to make his general point that this correction still doesn’t make Biden-era inflation sound good, but his specific number was, again, wrong. And he didn’t acknowledge that inflation fell sharply under Biden after hitting the 40-year high, declining to 2.9% in Biden’s last full month in office, December 2024, and 3.0% in January 2025, when Trump and Vance were inaugurated.The rate was 3.4% in July 2026, the most recent month for which data is available.Trump didn’t end taxes on Social SecurityVance claimed, “We’ve ended taxes on Social Security.” Several other convention speakers, including Rep. Lisa McClain of Michigan, Rep. Ryan Mackenzie of Pennsylvania and Ohio House candidate Derek Merrin, similarly said the administration has achieved “no tax on Social Security.”It hasn’t. The big domestic policy bill Trump signed in 2025 did create an additional, temporary $6,000-per-year tax deduction for individuals age 65 and older (which phases out for individuals earning $75,000 per year or more), but as the White House has implicitly acknowledged, millions of Social Security recipients will continue to pay taxes on their benefits even before the temporary new deduction expires after 2028.The Social Security Administration said in 2025 that “the bill ensures that nearly 90% of Social Security beneficiaries will no longer pay federal income taxes on their benefits.Claim about violent crime rate under BidenWhile criticizing the Biden administration, Vice President JD Vance claimed Thursday that the US “became a country where violent crime exploded, unless, of course, you could afford private security.”But violent crime did not explode under Biden. In fact, as FactCheck.org reported last month, data collected and published by the FBI shows that the national violent crime rate was at a lower level in 2023 and 2024, the last two full calendar years of Biden’s term, than it was in 2020, the last full calendar year of Trump’s first term. The year 2020 was highly unusual in many ways – violent crime jumped amid the Covid-19 pandemic – but Biden nonetheless left office with violent crime lower than it was when he took over. In fact, the 2024 violent crime rate was even lower than the 2019 rate under Trump before the pandemic.There was an increase in violent crime during the earlier part of Biden’s term. But given the subsequent decline, it’s misleading at best to claim violent crime “exploded” with no further context.Asked earlier this month about Trump’s similar previous claims to have reversed a Biden-era upswing in violence, crime data expert Jeff Asher said in an email: “No, crime began dropping significantly in 2023 during the Biden administration. Murder fell at record rates in 2023, 2024 and 2025 and, while 2026 may not feature a record decline nationally, it is still on track to see a sizable double-digit decline this year. Violent crime similarly fell nationally in 2023 and 2024, though the drops were more muted than the decline that was recorded by the FBI in 2025.”Other GOP speakersMike Johnson’s false claim about the inflation Republicans inherited from BidenSome other speakers at the convention took aim at inflation under Biden. House Speaker Mike Johnson claimed that “Republicans inherited from the Biden administration record-high inflation.”That’s not true. The inflation rate was 2.9% in Biden’s last full month in office, December 2024, and 3.0% in January 2025, when Trump took over. That’s lower than the most recent rate, 3.4% in July 2026, and nowhere close to the all-time record of 23.7%, which was reached in 1920, or the highest point of Jimmy Carter’s presidency, 14.8%, which was reached in 1980.Johnson correctly said moments later that inflation reached “a 40-year high of 9.1% inflation” under Biden. But a 40-year high is not an all-time record. More importantly, Johnson didn’t explain that 9.1% was much higher than the rate Trump inherited or that the 9.1% rate occurred in June 2022, with roughly two-and-a-half years left in Biden’s term.The cumulative increase in prices from the beginning of the Biden administration to the end was also not the highest in US history. Federal figures show that beginning-to-end inflation under Biden was less than half of that during Carter’s term.What Johnson left out of his claim about a congressional resolutionWhile attacking Democrats as extreme, Johnson said: “Just last week, nearly every Democrat in the House of Representatives voted against condemning socialism and Marxism. They voted against it.”But the resolution didn’t use the word “Marxism.” And Johnson didn’t mention that the resolution wasn’t only about condemning socialism. Rather, it contained other language that Democratic leadership said was the focus of the party’s opposition to the resolution.The resolution’s first provision said it “condemns and denounces socialism in all its forms, including the Democratic Socialists of America, and opposes the implementation of socialist policies in the United States.” But its fifth provision said it “calls for enactment of the SAVE America Act,” Trump’s favored elections bill, which contains various provisions opposed by many Democrats.So while it’s very possible many Democrats would have opposed the resolution even without its expression of support for the SAVE America Act, the call to pass this elections bill served as a poison pill that ensured most Democrats wouldn’t support it.“House Resolution 1490 explicitly calls for enactment of the so-called SAVE America Act, which is the top legislative priority of far-right extremists,” Democratic House leader Hakeem Jeffries said in a statement last week.A New Mexico candidate left out key context in an attack on his opponentGreg Cunningham, a Republican House candidate in New Mexico, used some of his Thursday speech to criticize his Democratic opponent, Rep. Gabe Vasquez. Cunningham said of Vasquez: “He even voted against a resolution honoring the sacrifices and service of the brave men and women in law enforcement who protect, every day, our communities.”But Cunningham left out important context about the resolution. While its focus was expressing support for law enforcement, its preamble contained statements praising the Trump administration and criticizing “leftist activists,” “progressive politicians” and “sanctuary city policies” for allegedly making law enforcement less safe.In other words, a House member might vote against such a resolution, as the vast majority of Democrats did, because they disagreed with conservative components of it, not the general expressions of support for law enforcement. (CNN has reached out to Vasquez’s campaign and House office for comment on his vote.) It’s common for parties to write resolutions in a way that would make it difficult for opponents to support but would open those opponents to campaign attacks if they voted “no.”An Ohio candidate’s misleading attack about Democrats and votingMerrin, the Republican candidate running against Democratic Rep. Marcy Kaptur for a House seat in Ohio, claimed in his speech, “While Democrats talk about letting illegal immigrants vote in our election, Republicans fight for proof of citizenship, photo ID and fair elections.”It’s a big country, so it’s possible some Democrat somewhere is talking about letting undocumented people vote in some election. But Merrin’s claim is misleading at best. There is no proposal from Democrats in Congress to let undocumented people vote in the 2026 midterms – the election Merrin appeared to be referring to when he said “our election” – or vote in future federal elections.CNN has reached out to Merrin’s campaign for an explanation of his claim.House Majority Leader Steve Scalise invoked a similar theme in his speech Wednesday, claiming that Democrats had voted last week “to allow illegals to vote in our federal elections.” But there was no congressional vote on letting undocumented immigrants vote in any elections.Rather, there was a vote on the non-binding Republican resolution that included multiple provisions, including one that “reiterates the notion that American elections are for American citizens only,” one supporting Trump’s favored elections bill and one denouncing socialism.Opposing that multi-clause resolution doesn’t necessarily mean someone supports voting by any non-citizens, let alone non-citizens in the country illegally.This article has been updated with additional items.CNN’s Deja Oliver contributed to this report.The-CNN-Wire™ & © 2026 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved.
Humans experimented with drugs 23,000 years earlier than we thought
Betel nut use among hunter-gatherers may turn back the clock.
Childhood Chemotherapy Leaves Lasting DNA Damage in Healthy Tissues
Certain chemotherapy drugs can age children’s healthy cells to levels comparable to those found in adult tissues.
Lil’ Drug Store Products acquires Navajo’s Health, Beauty and Wellness business
Lil’ Drug Store Products, Inc. (LDSP), based in Cedar Rapids, announced the completed acquisition of Navajo Incorporated‘s Health, Beauty, and Wellness business. The acquisition was completed Sept. 4, according to a release. Opened in 1974, the family-owned Lil’ Drug Store Products provides distribution, category management, and brand partnerships across various retail channels such as health […]
Lil’ Drug Store Products acquires Navajo’s Health, Beauty and Wellness business
Lil’ Drug Store Products, Inc. (LDSP), based in Cedar Rapids, announced the completed acquisition of Navajo Incorporated‘s Health, Beauty, and Wellness business. The acquisition was completed Sept. 4, according to a release. Opened in 1974, the family-owned Lil’ Drug Store Products provides distribution, category management, and brand partnerships across various retail channels such as health […]
Va. health dept. updates food allergen list, food establishment guidance
Businesses are not required to reprint existing menus and can offer a standalone handout or a QR code so customers can access the information. The protocols stem from the most recent food code update from the United States Food and Drug Administration — a mandate last revised in 2022.
Kratom ban meets quiet compliance as retailers clear shelves
Kratom was classified as a Schedule I drug on Aug. 28, as Gov. Maura Healey's administration sounded the alarm about the unregulated products that can lead to dangerous health effects. Inspectors fanned out across the state as the order went into effect to check for compliance.
Appeals court considers future of nationwide access to medication abortion
The issue of medication abortion was back before a New Orleans-based appeals court on Wednesday, in the latest iteration of a years-long legal effort to end the provision of abortion drugs via telehealth.
Scientists Discover the Earliest Evidence of Drug Use in Really Old Teeth
A hunter-gatherer who lived in Indonesia as early as 25,000 years ago may have regularly sucked on betel nuts to release their psychoactive properties.
Indonesian foragers may have sucked on mind-altering nuts 25,000 years ago, research finds
Analysis of two skeletons reveals tooth wear and traces of psychoactive substance in what may be earliest known evidence for human drug taking
Rubio visits Ecuador as Trump-friendly leader helps the US counterdrug push in the region
U.S. Secretary of State Marco Rubio visits Ecuador on the second leg of a three-nation tour of South America aimed at boosting security cooperation with conservative leaders.
Webinar: The Massive Scale of GLP-1s: Evolving Health, Healthcare and Markets
Watch this discussion on how GLP-1 drugs for obesity are changing the shape of U.S. healthcare. From direct-to-consumer portals to pharmacy deals, how these drugs reach patients is changing—and leading to debates over pricing and coverage. Learn how your company can be both patient-forward while also maximizing revenue in this unique environment.
Luma locks down 15-year, $410M fund for life science investments
Luma Group today announced the final close of its inaugural life sciences venture capital fund, totaling $410 million. The New York-based investment firm has had a grip on life sciences since its founding in 2023. The funds unveiled today, dubbed LumaBio Fund I, include investments that have already been made into more than 10 biotechs. They include the likes of eye disease-focused Character Biosciences, rebranded Belgian biotech Coultreon Biopharma and cellular rejuvenation company Altos Labs. The fund saw early success when one of the companies it co-founded, called Vaccine Company, was picked up by Eli Lilly earlier this year for up to $1.55 billion. The acquisition of the in vivo nanoparticle technology-focused biotech formed part of a trio of vaccine buys for the Big Pharma, which has itself been on a prolonged spending spree in 2026. Luma's fund is structured as a 15-year investment with plans to support groundbreaking science and support companies through key milestones from discovery to commercialization, Luma explained in the release. "We founded Luma Group on the belief that extraordinary science, supported by patient, long-term capital, has the power to improve millions of lives," Joshua Fink, founder and managing member of Luma Group, said in the release. "This fund represents more than capital—it is a commitment to partnering with extraordinary innovators as they translate visionary science into life-changing medicines."
The Cost of Cutting American Science: How Federal Cuts Diminish Public Health Capacity
Among the federal government’s many responsibilities is the work it does to protect public health. Federal agencies monitor our food supply to ensure safety, conduct research to better understand emerging health threats, provide funding for public health programs in communities and work to detect and respond to disease outbreaks. Americans rely on these efforts every day—in a 2024 online survey, 74% of respondents said that “if the federal government issued safety guidance about food you eat regularly,” they would follow it. Changes to Federal Public Health Capacity The Trump administration’s efforts to reshape the federal government have resulted in significant impacts on our nation’s public health capacity over the past 20 months, affecting the response to health concerns such as measles, Ebola and cyclosporiasis. Agencies with core public health, food safety and disease prevention responsibilities experienced large workforce decreases during the first year of the administration. At the Centers for Disease Control and Prevention, for instance, the workforce in February 2026 was 26.7% smaller than in September 2024 before the start of the Trump administration. The Food and Drug Administration saw a similarly steep decline of 21.6%. Agencies such as the National Institutes of Health, Substance Abuse and Mental Health Services Administration and Food Safety and Inspection Service also experienced large workforce decreases. (function(){function e(){window.addEventListener(`message`,function(e){if(e.data[`datawrapper-height`]!==void 0){var t=document.querySelectorAll(`iframe`);for(var n in e.data[`datawrapper-height`])for(var r=0,i;i=t[r];r++)if(i.contentWindow===e.source){var a=e.data[`datawrapper-height`][n]+`px`;i.style.height=a}}})}e()})(); Changes can also be seen in crucial public health occupations. The number of federal food inspectors, for example, decreased by more than half between September 2024 and February 2026, going from 1,035 to 473. This is the lowest number of food inspectors employed by the federal government since at least 2005. By February 2026, there were also 33.3% fewer federal public health program specialists, whose work includes advising federal funding recipients on public health activities and analyzing the effectiveness of public health programs. Government’s capacity is diminished as employees with specialized knowledge and experience in protecting the public and responding to health risks depart, leaving agencies less prepared to carry out their public health missions. There also have been vacancies in critical high-level leadership positions at public health agencies, most notably at the CDC, which had a permanent Senate-confirmed director for less than a month between January 2025 and early August 2026. Although the CDC has previously been led by acting directors at the start of an administration, the nearly yearlong gap since the departure of the administration’s first permanent director in August 2025 is without precedent. As of August 2026, the FDA is also currently without a Senate-confirmed commissioner following the previous commissioner’s resignation in May 2026. Additionally, public health agencies are experiencing increased politicization of their leadership ranks. In agencies such as the CDC and Food Safety and Inspection Service, the number of individuals in the Senior Executive Service—the most senior career leaders in government—has declined significantly, while at the same time the number of political appointees has reached record levels. (function(){function e(){window.addEventListener(`message`,function(e){if(e.data[`datawrapper-height`]!==void 0){var t=document.querySelectorAll(`iframe`);for(var n in e.data[`datawrapper-height`])for(var r=0,i;i=t[r];r++)if(i.contentWindow===e.source){var a=e.data[`datawrapper-height`][n]+`px`;i.style.height=a}}})}e()})(); (function(){function e(){window.addEventListener(`message`,function(e){if(e.data[`datawrapper-height`]!==void 0){var t=document.querySelectorAll(`iframe`);for(var n in e.data[`datawrapper-height`])for(var r=0,i;i=t[r];r++)if(i.contentWindow===e.source){var a=e.data[`datawrapper-height`][n]+`px`;i.style.height=a}}})}e()})(); At the CDC, for example, the number of career SES decreased 42.9% between December 2024 and February 2026, while the number of non-Senate confirmed political appointees at the agency was six times larger than the agency’s historical average from 2009 and 2024. Knowledgeable career leaders are integral to the ability of public health agencies to carry out their work with scientific integrity and professional judgment, and rapid leadership turnover and increased politicization threaten agencies’ ability to make evidence-based decisions to protect our health. The upheaval and politicization in public health agencies have also negatively affected employee engagement. Strong employee engagement is crucial to the ability of agencies to carry out their mission and successfully provide essential services to the public. In the 2025 Public Service Viewpoint Survey conducted by the Partnership for Public Service, the Department of Health and Human Services—which encompasses major public health agencies such as the CDC and FDA—had an employee engagement and satisfaction score of 20.4 out of 100, one of the lowest among large agencies. Only 2.8% of HHS employees indicated trust in their political leaders and only 8.7% reported confidence that they could report a suspected violation of law or regulation without retaliation. Employees at HHS also reported that the agency’s ability to provide services to the public had suffered. Nearly half of employees at HHS, 47.5%, said their work unit was worse at delivering quality services compared to its performance in 2024. In addition, 57.8% said their work unit was performing worse at fulfilling stakeholder needs. In addition to the work done within federal agencies, the federal government also distributes significant funding for public health and disease prevention work to state and local governments, nonprofits and small businesses—funding which has been significantly disrupted. At the CDC, for example, there was a 71.9% decrease in the amount of project grant funding issued in fiscal year 2025 compared to fiscal year 2024. The FDA also issued far less funding in fiscal year 2025—a 21.3% decrease from its fiscal year 2024 funding. Changes in federal funding include the ending of grants to community organizations that worked on HIV prevention and the cancellation of funding for research into improvements to patient safety and healthcare quality. These changes go beyond federal agencies to impact the broader public health ecosystem, including the state and local health departments responsible for much of the on-the-ground public health work in their communities. About 80% of the CDC’s domestic funding is directed towards state and local partners—meaning that cuts to CDC funding can ultimately result in cuts to state and local public health capacity. Federal agencies also provide expertise and assistance to state and local health agencies as they deal with particular health challenges, but workforce cuts have resulted in fewer federal employees available to help. The Impact of Changes to Public Health Capacity These changes to federal public health capacity are not abstract concerns. Disrupted programs, reduced funding and lost expertise at public health agencies across all levels of government threaten the public’s physical well-being and safety. In some cases, this has already led to harm. The most immediate impacts of federal cuts were seen in interruptions to ongoing public health programs and crisis responses. In one instance, when CDC grants were canceled during the 2025 Texas measles outbreak—the most severe measles outbreak in 25 years—public health officials in Lubbock, Texas were forced to pause parts of their measles response work supported by the frozen funding. Lubbock’s director of public health further said that a lack of available CDC experts to reach out to for advice “definitely” impacted the department’s response to the measles crisis. Cuts to federal funding also forced Dallas County Health and Human Services to cut staff and cancel 50 community vaccination clinics during the outbreak. Public health work outside of major outbreak responses was also disrupted. For example, in April 2025, the Milwaukee Public Health Department was unexpectedly unable to reach experts on lead poisoning due to firings at the CDC when responding to concerns about lead contamination in Milwaukee public schools. Due to federal workforce cuts, several programs at the CDC, including Alzheimer’s and epilepsy programs, have also become trapped in limbo—existing on paper, but without the staff necessary to operate. More recent crises reveal how federal cuts have weakened the public health infrastructure needed to prevent and respond to dangerous new outbreaks. Internationally, cuts at the U.S. Agency for International Development eliminated funding for disease testing and contact tracing abroad, which delayed detection of and responses to the 2026 Ebola outbreak in the Democratic Republic of Congo. While international outbreaks may seem far removed, the unchecked spread of disease in any country can quickly pose a danger to economic well-being, security and health around the world. Within the United States, public health cuts inhibited responses to the summer 2026 outbreak of the food-borne parasite cyclospora. At the federal level, cuts to funding for lab equipment and for CDC staff with expertise in parasitic infections—including 9 out of 11 staff members at the lab responsible for identifying parasitic outbreaks in 2025— contributed to the largest reporting delay in outbreak cases at the CDC in 15 years. Conflicting communications from the FDA about the source of the outbreak, which followed cuts to the agency’s communications department, additionally led to confusion among the public about how to best avoid infection. At the same time, cuts to HHS funding and support for local and state public health slowed some health departments’ responses to the crisis. The exact costs of these delays, constraints and confusion in public health responses are difficult to estimate. However, their message is clear: federal cuts have already made containing threats to public health even more of a challenge. Conclusion Protecting public health—from food safety to disease prevention—is one of the federal government’s most important missions. Dramatic and haphazard cuts to federal agencies and funding have already disrupted the public health system, impacting the response to challenges such as measles, lead poisoning and cyclosporiasis. The U.S. public health system needed improvement before these disruptions. Since 2022, federal leadership and coordination in response to public health outbreaks has been on the Government Accountability Office’s High-Risk List of areas in need of attention to improve government effectiveness and efficiency. Recent cuts only compound these concerns. The chaotic dismantling of government and resulting disruptions to crucial functions like public health and disease prevention highlight the need for meaningful reform and concrete policy proposals to reimagine how government can better serve the public and be more effective, responsive and accountable. To learn more about the impact of federal cuts to public health and science more broadly, visit The Cost of Cutting American Science. Learn more For more information on the Partnership for Public Service’s government reform initiative, visit Government for a New Era. View here In line with The Cost of Cutting American Science, federal workforce data in this brief is as of February 2026
The Cost of Cutting American Science: How Federal Cuts Diminish Public Health Capacity
Among the federal government’s many responsibilities is the work it does to protect public health. Federal agencies monitor our food supply to ensure safety, conduct research to better understand emerging health threats, provide funding for public health programs in communities and work to detect and respond to disease outbreaks. Americans rely on these efforts every day—in a 2024 online survey, 74% of respondents said that “if the federal government issued safety guidance about food you eat regularly,” they would follow it. Changes to Federal Public Health Capacity The Trump administration’s efforts to reshape the federal government have resulted in significant impacts on our nation’s public health capacity over the past 20 months, affecting the response to health concerns such as measles, Ebola and cyclosporiasis. Agencies with core public health, food safety and disease prevention responsibilities experienced large workforce decreases during the first year of the administration. At the Centers for Disease Control and Prevention, for instance, the workforce in February 2026 was 26.7% smaller than in September 2024 before the start of the Trump administration. The Food and Drug Administration saw a similarly steep decline of 21.6%. Agencies such as the National Institutes of Health, Substance Abuse and Mental Health Services Administration and Food Safety and Inspection Service also experienced large workforce decreases. (function(){function e(){window.addEventListener(`message`,function(e){if(e.data[`datawrapper-height`]!==void 0){var t=document.querySelectorAll(`iframe`);for(var n in e.data[`datawrapper-height`])for(var r=0,i;i=t[r];r++)if(i.contentWindow===e.source){var a=e.data[`datawrapper-height`][n]+`px`;i.style.height=a}}})}e()})(); Changes can also be seen in crucial public health occupations. The number of federal food inspectors, for example, decreased by more than half between September 2024 and February 2026, going from 1,035 to 473. This is the lowest number of food inspectors employed by the federal government since at least 2005. By February 2026, there were also 33.3% fewer federal public health program specialists, whose work includes advising federal funding recipients on public health activities and analyzing the effectiveness of public health programs. Government’s capacity is diminished as employees with specialized knowledge and experience in protecting the public and responding to health risks depart, leaving agencies less prepared to carry out their public health missions. There also have been vacancies in critical high-level leadership positions at public health agencies, most notably at the CDC, which had a permanent Senate-confirmed director for less than a month between January 2025 and early August 2026. Although the CDC has previously been led by acting directors at the start of an administration, the nearly yearlong gap since the departure of the administration’s first permanent director in August 2025 is without precedent. As of August 2026, the FDA is also currently without a Senate-confirmed commissioner following the previous commissioner’s resignation in May 2026. Additionally, public health agencies are experiencing increased politicization of their leadership ranks. In agencies such as the CDC and Food Safety and Inspection Service, the number of individuals in the Senior Executive Service—the most senior career leaders in government—has declined significantly, while at the same time the number of political appointees has reached record levels. (function(){function e(){window.addEventListener(`message`,function(e){if(e.data[`datawrapper-height`]!==void 0){var t=document.querySelectorAll(`iframe`);for(var n in e.data[`datawrapper-height`])for(var r=0,i;i=t[r];r++)if(i.contentWindow===e.source){var a=e.data[`datawrapper-height`][n]+`px`;i.style.height=a}}})}e()})(); (function(){function e(){window.addEventListener(`message`,function(e){if(e.data[`datawrapper-height`]!==void 0){var t=document.querySelectorAll(`iframe`);for(var n in e.data[`datawrapper-height`])for(var r=0,i;i=t[r];r++)if(i.contentWindow===e.source){var a=e.data[`datawrapper-height`][n]+`px`;i.style.height=a}}})}e()})(); At the CDC, for example, the number of career SES decreased 42.9% between December 2024 and February 2026, while the number of non-Senate confirmed political appointees at the agency was six times larger than the agency’s historical average from 2009 and 2024. Knowledgeable career leaders are integral to the ability of public health agencies to carry out their work with scientific integrity and professional judgment, and rapid leadership turnover and increased politicization threaten agencies’ ability to make evidence-based decisions to protect our health. The upheaval and politicization in public health agencies have also negatively affected employee engagement. Strong employee engagement is crucial to the ability of agencies to carry out their mission and successfully provide essential services to the public. In the 2025 Public Service Viewpoint Survey conducted by the Partnership for Public Service, the Department of Health and Human Services—which encompasses major public health agencies such as the CDC and FDA—had an employee engagement and satisfaction score of 20.4 out of 100, one of the lowest among large agencies. Only 2.8% of HHS employees indicated trust in their political leaders and only 8.7% reported confidence that they could report a suspected violation of law or regulation without retaliation. Employees at HHS also reported that the agency’s ability to provide services to the public had suffered. Nearly half of employees at HHS, 47.5%, said their work unit was worse at delivering quality services compared to its performance in 2024. In addition, 57.8% said their work unit was performing worse at fulfilling stakeholder needs. In addition to the work done within federal agencies, the federal government also distributes significant funding for public health and disease prevention work to state and local governments, nonprofits and small businesses—funding which has been significantly disrupted. At the CDC, for example, there was a 71.9% decrease in the amount of project grant funding issued in fiscal year 2025 compared to fiscal year 2024. The FDA also issued far less funding in fiscal year 2025—a 21.3% decrease from its fiscal year 2024 funding. Changes in federal funding include the ending of grants to community organizations that worked on HIV prevention and the cancellation of funding for research into improvements to patient safety and healthcare quality. These changes go beyond federal agencies to impact the broader public health ecosystem, including the state and local health departments responsible for much of the on-the-ground public health work in their communities. About 80% of the CDC’s domestic funding is directed towards state and local partners—meaning that cuts to CDC funding can ultimately result in cuts to state and local public health capacity. Federal agencies also provide expertise and assistance to state and local health agencies as they deal with particular health challenges, but workforce cuts have resulted in fewer federal employees available to help. The Impact of Changes to Public Health Capacity These changes to federal public health capacity are not abstract concerns. Disrupted programs, reduced funding and lost expertise at public health agencies across all levels of government threaten the public’s physical well-being and safety. In some cases, this has already led to harm. The most immediate impacts of federal cuts were seen in interruptions to ongoing public health programs and crisis responses. In one instance, when CDC grants were canceled during the 2025 Texas measles outbreak—the most severe measles outbreak in 25 years—public health officials in Lubbock, Texas were forced to pause parts of their measles response work supported by the frozen funding. Lubbock’s director of public health further said that a lack of available CDC experts to reach out to for advice “definitely” impacted the department’s response to the measles crisis. Cuts to federal funding also forced Dallas County Health and Human Services to cut staff and cancel 50 community vaccination clinics during the outbreak. Public health work outside of major outbreak responses was also disrupted. For example, in April 2025, the Milwaukee Public Health Department was unexpectedly unable to reach experts on lead poisoning due to firings at the CDC when responding to concerns about lead contamination in Milwaukee public schools. Due to federal workforce cuts, several programs at the CDC, including Alzheimer’s and epilepsy programs, have also become trapped in limbo—existing on paper, but without the staff necessary to operate. More recent crises reveal how federal cuts have weakened the public health infrastructure needed to prevent and respond to dangerous new outbreaks. Internationally, cuts at the U.S. Agency for International Development eliminated funding for disease testing and contact tracing abroad, which delayed detection of and responses to the 2026 Ebola outbreak in the Democratic Republic of Congo. While international outbreaks may seem far removed, the unchecked spread of disease in any country can quickly pose a danger to economic well-being, security and health around the world. Within the United States, public health cuts inhibited responses to the summer 2026 outbreak of the food-borne parasite cyclospora. At the federal level, cuts to funding for lab equipment and for CDC staff with expertise in parasitic infections—including 9 out of 11 staff members at the lab responsible for identifying parasitic outbreaks in 2025— contributed to the largest reporting delay in outbreak cases at the CDC in 15 years. Conflicting communications from the FDA about the source of the outbreak, which followed cuts to the agency’s communications department, additionally led to confusion among the public about how to best avoid infection. At the same time, cuts to HHS funding and support for local and state public health slowed some health departments’ responses to the crisis. The exact costs of these delays, constraints and confusion in public health responses are difficult to estimate. However, their message is clear: federal cuts have already made containing threats to public health even more of a challenge. Conclusion Protecting public health—from food safety to disease prevention—is one of the federal government’s most important missions. Dramatic and haphazard cuts to federal agencies and funding have already disrupted the public health system, impacting the response to challenges such as measles, lead poisoning and cyclosporiasis. The U.S. public health system needed improvement before these disruptions. Since 2022, federal leadership and coordination in response to public health outbreaks has been on the Government Accountability Office’s High-Risk List of areas in need of attention to improve government effectiveness and efficiency. Recent cuts only compound these concerns. The chaotic dismantling of government and resulting disruptions to crucial functions like public health and disease prevention highlight the need for meaningful reform and concrete policy proposals to reimagine how government can better serve the public and be more effective, responsive and accountable. To learn more about the impact of federal cuts to public health and science more broadly, visit The Cost of Cutting American Science. Learn more For more information on the Partnership for Public Service’s government reform initiative, visit Government for a New Era. View here In line with The Cost of Cutting American Science, federal workforce data in this brief is as of February 2026
Scientists Who Study Sleep and Narcolepsy Win Prestigious Lasker Award
The two researchers have won a prestigious Lasker Award. Their findings laid the groundwork for a new drug that addresses the sleep disorder’s root cause.
FBI raided his Detroit drug rehab centers. Now he can't pay employees.
A drug rehab center in metro Detroit says the FBI has seized all of its money, causing paychecks to bounce and leaving patients with nowhere to go.
Scientists and algorithms: Finding the right balance in modern drug development
The future of drug development is not scientists versus algorithms. It is scientists and algorithms working together.
Licensed counselor reveals link between weight loss and mental health effects
Bonnie Mitchell, a licensed professional clinical counselor in California, said that while a new study shows a correlation between weight-loss drug use and self-reported mental health symptoms, it cannot prove causation.
U.S. Department of Health announces key leadership changes at FDA
The U.S. Department of Health and Human Services on Tuesday named four senior leaders at the U.S. Food and Drug Administration, including the heads of its drug center and vaccines and biologics unit.
U.S. Department of Health Announces Key Leadership Changes at FDA
Sept 8 (Reuters) - The U.S. Department of Health and Human Services on Tuesday named four senior leaders at the U.S. Food and Drug Administration, including the heads of its drug center and vaccines and biologics unit. (Reporting by Christy Santhosh in Bengaluru; Editing by Tasim ...
HHS Announces Key Leadership Selections at FDA to Promote Innovation, Reform, and National Health Priorities
The U.S. Department of Health and Human Services today announced the selection of four senior leaders at the U.S. Food and Drug Administration.
Drug developed for lung disease may slow biological aging in surprising ‘bonus’
Rentosertib, an AI-discovered drug for idiopathic pulmonary fibrosis, made patients appear three to four years biologically younger in a clinical trial.
California’s healthcare affordability office claims power to punish overspending hospitals
Hospital executives argue much of their spending, like drug costs and labor, is outside their control.
Egyptian TV presenter Sarah Khalifa sentenced to death in drug case
Egyptian TV presenter Sarah Khalifa has been sentenced to death for an alleged drug trafficking scheme.
AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD
With a detailed data drop that AstraZeneca’s R&D chief described as an internal “science success story,” the British Big Pharma has secured an FDA priority review for what it believes could become a flagship biologic in chronic obstructive pulmonary disease (COPD). In detailed results from the late-stage Oberon and Titania trials—first teased in March and detailed in full at the European Respiratory Society Congress in Barcelona this week—the drugmaker laid out the extent of its IL-33 inhibitor’s potential to reduce moderate and severe exacerbations in a wide range of COPD patients still struggling with those “lung attacks,” as AstraZeneca’s Sharon Barr, Ph.D., called them, despite using standard-care inhaled therapy. In the headline results, a 300 mg dose of tozorakimab given once every four weeks curbed those moderate and severe exacerbations in the studies’ primary population of former smokers by 29% in the Oberon study and 34% in Titania. In the overall population of both current and former smokers, these reductions were 30% and 29%, respectively, versus placebo and inhaled standard of care. The benefits also extended to clinically meaningful exacerbation reductions in all prespecified patient subgroups and specifically turned up promising signals in patients across a range of blood eosinophil counts, with Barr telling Fierce that “it’s the details that make this even more exciting than the high-level results that we’ve already shared.” In fact, during AZ’s tozorakimab poster presentation at the ERS 2026 Congress this past weekend, attendees were so enamored by the data that event organizers had to encourage people to clear the room and look at the other presentations on offer, Barr said in an interview. “I think it really speaks to the fact that there is a lot of buzz around these data because the entire respiratory community has been so desperate for new therapies for these patients,” she explained. The respiratory disease continues to represent a “staggering unmet medical need,” Barr said, highlighting the COPD exacerbations that the Oberon and Titania studies homed in on, which she added carry a greater mortality risk than a heart attack. “When a patient has a severe exacerbation, only about half of them are still alive within three and a half years,” she pointed out. As for tozorakimab specifically, Barr christened the molecule “an AstraZeneca science success story,” harkening several years back to the point at which researchers began to explore IL-33 as a driver of respiratory disease, and COPD in particular. At the same time, “there was still so much that wasn’t understood,” she admitted, highlighting the insight that IL-33 signals through both ST2 and EGFR through the RAGE pathway, a discovery Barr attributed to AstraZeneca's own scientists. Understanding the need to tackle both pathways in COPD—and aware of competitor candidates in the hopper, including one that bound ST2—the company ultimately had to make some “courageous decisions,” Barr said. These included taking a prior COPD molecule offline and going back to the drawing board to reinvent its potential IL-33 label “to make sure that we had a molecule that could block signaling through both arms of the pathway, through both the reduced form and the oxidized form, knowing that we wouldn’t be first, but striving to be best.” “When we put [tozorakimab] into the clinic, we firmly believed that we had a differentiated molecule, and we saw the other molecules blocking just ST2 or partially blocking IL-33, unable to deliver two positive pivotal studies in COPD,” Barr explained. “We kept marching forward because we believed our molecule was differentiated, and now I think we have the clinical validation that supports that.” Ultimately, AstraZeneca finds itself on much better footing these days when it comes to potential biologic rivals to tozorakimab in COPD. Sanofi and Regeneron’s Dupixent, for instance, is approved to treat COPD exacerbations in patients with high eosinophil counts, but not low ones. Meanwhile, the future has become cloudier for other next-gen IL-33 candidates from Sanofi and Regeneron, as well as Roche, which have suffered trial flops in recent years. One other potential ingredient for AstraZeneca’s success in its duo of studies was that the company was “ambitious in the trial design, willing to look at an all-comers population,” Barr said, “and willing to enroll the most severe patients.” Prior studies for would-be biologics rivals in COPD “avoided enrolling” those patients, she pointed out. She also highlighted the Big Pharma’s painstaking design of exacerbations in its trial, which “gave us a very rigorous readout,” and pointed to “the extra effort and investment” the company put in to understand the effect of mucus plugs in patients. Barr described mucus production as a “key feature in disease diversity,” noting that mucus plugs—obstructing clumps of mucus that block patients’ airways—are associated with worse outcomes in COPD. In its data announcement, AstraZeneca noted that an integrated analysis of Oberon and Titania found tozorakimab “demonstrated a reduction in patients’ mucus plug score,” with the pharma claiming its biologic is the first to deliver such results in a broad COPD population. “So being able to reduce those mucus plugs, we expect, is an important part of driving benefit for patients who are living with COPD,” Barr said. Again touching on the breadth of the study populations, Barr added that tozorakimab “worked across all eosinophil levels in both current and former smokers across all levels of lung function,” which she suggested “really simplifies decision-making for clinicians, and it allows them to offer therapy to the broadest possible patient population.” In the highest patient eosinophil count group, tozorakimab helped chart a 43% reduction in exacerbation risk, which Barr stressed were “unprecedented data.” In the mid-level group, AZ’s drug delivered a 23% reduction and, in the lowest group, a 34% reduction in eosinophils, which Barr said suggests efficacy “in all patient subgroups.” As for AZ’s recent guidance upgrade on the medicine’s sales opportunity, the lift from a $3 billion to $5 billion range to $5 billion plus was informed by multiple factors, Barr said, including the fact that “in 2024, there were multiple competitors, and there aren’t anymore.” Additionally, “we know that this is a massive unmet medical need, and this is a really incredible set of data that we think will be very convincing to the clinical community,” Barr said. Looking ahead to a potential evolution of the COPD treatment landscape, Barr noted that most patients start treatment in the community with an option like a triple therapy, and for them, having an option like AstraZeneca’s inhaler Breztri will remain a “really important part” of that journey. But of the patients uncontrolled on triple therapy, which Barr described as “about half of them today,” just a “small fraction” are currently eligible for biologic therapy, which she emphasized AstraZeneca is working to change. Understanding that COPD is not a “one-size-fits-all” disease, AstraZeneca is also looking at its antibody drug Tezspire for patients with T2-driven disease, and the company continues to think about new mechanisms for tackling COPD through both systemic and inhaled drugs, Barr said.
Why a cannabis business is betting on dogs to reach FDA approval
Endovia is pursuing FDA veterinary approval for its cannabinoid drug targeting canine cancer and chronic pain in the companion-animal market.
Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI) (“Optimi” or the “Company”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held September 14-16, 2026, at the Lotte New York Palace Hotel. A Company presentation will be available on demand here beginning Friday, Septem
Ozempic and Wegovy may have an unexpected mental health benefit
Semaglutide, the drug behind Ozempic and Wegovy, may have benefits that extend well beyond weight loss and diabetes. In a large Swedish study of nearly 15,000 people with bipolar disorder, its use was linked to a 21% lower risk of psychiatric hospitalization. Researchers think effects on inflammation and brain-related biological pathways could help stabilize mood, though other GLP-1 drugs did not show the same association.
Names in the News: People shaping the future of Lake Area business
Pitre earns certification Calcasieu Parish Sheriff Stitch Guillory is pleased to announce the recent graduation of CPSO Deputy Monique Pitre from the Drug Abuse Resistance Education (D.A.R.E.) Instructor certification course. […]
How 2026 candidates are targeting health care "corruption"
They're accusing opponents of being in the pockets of drugmakers or health insurers.
Americans aren't divided on health care. Washington is.
Drug pricing. Medicaid. Medicare. The ACA. Substance use treatment. On every one of these fronts, bipartisan majorities want government to do more.
The Market Forces Quietly Adding Thousands to Patient Bills
The true cost of “vertical integration”: patients directed to a higher-priced location for procedures. Or forced to buy from their insurer’s wholly owned pharmacy, which may not stock the drug prescribed or provide it at the lowest price.
California’s healthcare affordability office claims power to punish overspending hospitals
New penalties can fine California hospitals and insurers up to 125% of their overspending, with enforcement starting as early as 2028. Hospital executives argue that much of their spending, like drug costs and labor, is outside their control.
Jackson County Behavioral Health to host presentations on youth safety, drug trends & digital world
Jackson County Behavioral Health to host presentations on youth safety, drug trends & digital world
Egyptian TV presenter Sarah Khalifa sentenced to death on drug charges
Khalifa denied the charges and plans to appeal the death sentence, per her lawyer.
TV presenter Sarah Khalifa sentenced to death in Egypt on drug charges
Sarah Khalifa, an Egyptian TV presenter and lifestyle influencer, has been sentenced to death as part of a sprawling drug case.
Jackson County Behavioral Health to host presentations on youth safety, drug trends & digital world
According to their press release, it’s addressing current drug trends, social media, AI, sextortion and other issues affecting youth and families.
Cravings ‘like heroin withdrawal’: what happens when weight-loss drugs don’t work?
GLP-1 medications have been a gamechanger in the fight against obesity. But for a minority of patients, their impact is negligible. Why?
Prof Elizabeth Streicher unravels the science behind drug-resistant TB
Prof Elizabeth Streicher of the Division of Molecular Biology and Human Genetics delivered her inaugural lecture on Tuesday 1 September 2026. Her research focuses on the transmission and spread of Tuberculosis (TB). Knowing where TB transmission is happening can help to stop it from spreading. Prof Elizabeth Streicher of the Division of Molecular Biology and Human Genetics in the Faculty of Medicine and Health Sciences delivered her inaugural lecture on Tuesday 1 September 2026. The title of her lecture was Decoding tuberculosis: the evolution of technology, epidemiology and the Mycobacterium tuberculosis genome. Streicher explained to Corporate Communication and Marketing how molecular epidemiology (using genetic information to track how and why diseases spread through populations) has improved our understanding of where drug-resistant TB comes from, how it spreads and how drug resistance evolves within and between populations. Tell us more about your research and why you became interested in this specific field. Overall, our research group studies the genome (complete set of DNA instructions found in a cell) of Mycobacterium tuberculosis, the bacteria that cause tuberculosis (TB) disease. Various regions of the genome are interrogated to study different aspects of the disease. My main focus has been on the epidemiology of tuberculosis – how the bacteria’s genome changes over time and what this tells us about the transmission and spread of the disease. How would you describe the relevance of your work? If we understand how the bacteria that cause TB change and spread, it can assist in combating TB globally. How has molecular epidemiology helped improve our understanding of drug-resistant TB? Molecular epidemiology was very important in drug-resistant TB as it was originally believed that bacteria that become resistant to antibiotics would be less fit and not be able to transmit. But it was shown that they can transmit, and therefore have to be monitored to identify hotspots of transmission and outbreaks, etc. Can you tell us briefly about the spoligotyping technique and its advantages for studying drug-resistant TB? Spoligotyping (a molecular technique used to identify and track specific strains of TB bacteria) does not detect drug resistance, but since the technique is relatively quick to do, it can be very useful in real-time situations, e.g. to monitor outbreaks of drug resistance. Why are interrupting transmission chains and identifying genomic hotspots important for controlling the spread of TB? Knowing where TB transmission is happening can assist in allocating resources to those areas to stop future transmission and spread of TB. Higher education can be challenging. What keeps you motivated when things get tough? Students – how they are so passionate and dedicated to learning and contributing to research and society as a whole. What aspects of your work do you enjoy the most? Again, the students and colleagues! But also the fact that it is continuously changing and thereby we are learning and expanding our knowledge. In the end, I know that we contribute to a better society in our small way. Tell us something exciting about yourself that people would not expect. Even though I love hiking (day and multi-day hikes) and being outside, I really do not like camping! How do you spend your free time? I love hiking (wellbeing in nature) and like to watch most sports. ©Higher Education Media Services. Subscribe
Early Data Indicates an A.I.-Generated Drug Could Slow Aging
Artificial intelligence was used to help develop a drug candidate, rentosertib, for a rare lung condition. Its maker says the drug also seems to reduce the biological hallmarks of age.
Students turned drug dealers: How some US fraternities entered the narcotics business
The case of 13 Penn State students charged with trafficking is the latest example of undergraduates who traded textbooks for selling illegal substances
A $480,000-a-year pill reflects a new normal for cancer drugs
Cancer drug prices have steadily increased. The expense is borne by government programs like Medicare, employers, patients and Americans who pay taxes and health insurance premiums.
Missouri candidate charged with trying to plant cocaine on his political rival
A candidate for the Missouri House faces a federal drug charge accusing him of trying to plant cocaine and Adderall on his Republican primary opponent.
Missouri candidate charged with trying to plant cocaine on his political rival
A candidate for the Missouri House faces a federal drug charge accusing him of trying to plant cocaine and Adderall on his Republican primary opponent.
Missouri candidate charged with trying to plant cocaine on his political rival
A candidate for the Missouri House faces a federal drug charge accusing him of trying to plant cocaine and Adderall on his Republican primary opponent.
U.S. Military Sinks Boats Said to Aid Drug Smuggling Near Ecuador
Unlike dozens of similar strikes, no one was killed after people suspected of drug smuggling were removed from what the U.S. military described as a floating refueling station.
Trump’s latest clemency grants aid a union boss and a Jay-Z associate
President Donald Trump issued 30 clemency grants on Thursday, including for a drug dealer-turned-executive of Roc Nation, Jay-Z’s sprawling company.
The Heart Drug Pelacarsen Fails, Shocking Novartis and Cardiologists
Doctors were hopeful the drug, which was being tested in a large clinical trial by Novartis, was going to be a powerful new tool to fight heart disease.
New pancreatic cancer drug could add to employers’ health bills
Rasonque’s approval is an exciting development in the fight to cure cancer, but could further challenge employers to carefully manage use.
Four Years of Lower Drug Prices: Real Savings, Unfinished Business
The administration is touting these agreements as proof that drug prices are coming down. However, we don’t have the evidence to back that up.
Cancer drug tames atherosclerosis inflammation and plaque in animal models
A new Yale study has identified a promising therapeutic avenue for atherosclerosis, a condition caused by inflammation and plaque buildup in arteries. Martin Schwartz, Ph.D., Robert W. Berliner Professor ...
Kentucky Sues Mayday Health Over Abortion Pill Advertising
Kentucky is the latest state to take action against the nonprofit Mayday Health for advertising that points people to a website providing information about abortion-inducing drugs.
Scientists map key protein interactions linked with profound autism
Research published in the journal Science illuminates a "missing piece" in the biological understanding of profound autism and offers new targets for drug development.
Allegheny County Health Department cuts ribbon on renovated McKeesport clinic
The McKeesport Public Health Office was renovated to include a new sexual health clinic, drug testing services, and more.
Missouri candidate charged with trying to plant cocaine on his political rival
JEFFERSON CITY, Mo. (AP) — A candidate for the Missouri House made an initial court appearance Thursday on a federal drug charge accusing him of trying to plant
Health benefit costs to jump 8.2% in 2027, highest since 2003
Marsh survey finds GLP-1 drugs, AI billing, and No Surprises Act disputes are each adding a full percentage point to trend
Nick Kyrgios cleared for immediate tennis return after stunning drug ban reversal
Just weeks after facing the prospect of years away from tennis, Nick Kyrgios has been handed a stunning lifeline following a major suspension ruling.
7 Science-Backed Ways to Curb Your Appetite—Without Weight-Loss Drugs
While our appetite-control system is quite complex, there are easy ways to help you feel fuller for longer for better digestion and weight loss.
GOP candidate gets busted trying to plant drugs on his political rival
Thomas Ross allegedly conspired to plant cocaine and Adderall in his Republican rival's purse, but his campaign manager wore a wire for the FBI.
Carla Jeffery’s family denies drugs played a part in Disney Channel star’s death
The “Zombies” star died at the age of 33 on Wednesday.
Carla Jeffery’s family denies drugs played a part in Disney star’s death
Carla Jeffery, known for Disney Channel’s ‘Zombies,’ died at the age of 33 on Wednesday; a cause of death was not immediately revealed.
Missouri candidate charged with trying to plant cocaine on his political rival
A candidate for the Missouri House has made an initial court appearance on a federal drug charge accusing him of trying to plant cocaine and Adderall on his Republican primary opponent.
Maduro asks judge to drop federal drug-trafficking case
Attorneys for Venezuela's former president Nicolas Maduro and wife, Cilia Flores, say they have something called "sovereign immunity"
Maduro asks judge to drop federal drug-trafficking case
Attorneys for Venezuela's former president Nicolas Maduro and wife, Cilia Flores, say they have something called "sovereign immunity"
Police: 'Major drug offender' arrested, charged with trafficking in Central Business District
A man has been arrested for drug trafficking after more than $230,000 and multiple firearms were recovered, according to Cincinnati police.
Court docs: Candidate accused of trying to plant drugs on political opponent
Court documents have revealed why a southwestern political candidate was facing a federal charge.Federal prosecutors charged Thomas Christopher Ross, 37, of Jop
GoodRx offers health subscription for families, to launch as employee benefit in 2027
GoodRx, a prescription drug savings site, announced on Thursday a family healthcare subscription for access to common medical services and over 250 medications, and it plans to launch the program as part of employer health benefits in 2027.
Billionaire family offices back health care and biotech startups in August
The personal investment firms of titans like Stanley Druckenmiller are backing innovations in gene editing, drug discovery and more.
Inflation is a drug and Washington is high on it
High prices have turned Americans against the economy, and they’re starting to unleash real consequences for Washington and the financial markets.
HHS announces $77M in grants to curb drug addiction, prevent suicide
The agency said $22 million will be sent to community-based initiatives to aid areas hit hardest by the opioid crisis.
Millions get wrong genetic test, study finds
A study shows current testing is providing false reassurance about genetic disposition for a rare life-threatening drug reaction.
Martin Scorsese says Tribeca neighborhood used to be ‘really good for’ stealing hubcaps, sex, and drugs at night (exclusive)
Martin Scorsese reminisces about New York’s crime-ridden Tribeca neighborhood in an exclusive clip from the upcoming documentary ‘Tribeca 25,’ premiering on Netflix Sept. 11.
Martin Scorsese says Tribeca neighborhood used to be ‘really good for’ stealing hubcaps, sex, and drugs at night (exclusive)
Scorsese reminisces about the New York hotspot with Robert De Niro in the new documentary “Tribeca 25,” premiering on Netflix on Sept. 11.
Health Brief: More drugmakers cut pricing deals
Plus: Nonprofits break down foreign aid cuts amid Trump administration shift to global health strategy
WATCH: Trump says 'Medicare for All' doesn't work
The president was asked about Democratic candidates who want to use Medicare to provide universal access to health care — and he said his approach to have confidential drug pricing deals was superior.
WATCH: Trump says more pharmaceutical companies will lower drug prices
Trump: 90% of prescription drugs covered by 'most favored nation' price deals
Several of the companies that agreed to lower drug prices also announced U.S. research and development investments Monday
Why doctors still can’t predict which migraine drug will work
Migraine prevention drugs are more targeted than ever before, and new guidelines may help doctors predict which will work for each patient.
Hims & Hers offers GLP-1 weight-loss drugs, men's health treatments in Australia
Telehealth company Hims & Hers said on Monday it has begun offering branded GLP-1 weight-loss drugs and other treatments to men in Australia as it continues to expand its international business.